Kura Oncology (KURA) Stock Forecast, Price Target & Predictions
KURA Stock Forecast
Kura Oncology stock forecast is as follows: an average price target of $19.00 (represents a 147.07% upside from KURA’s last price of $7.69) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
KURA Price Target
The average price target for Kura Oncology (KURA) is $19.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $27.00 to $11.00. This represents a potential 147.07% upside from KURA's last price of $7.69.
KURA Analyst Ratings
According to 4 Wall Street analysts, Kura Oncology's rating consensus is 'Buy'. The analyst rating breakdown for KURA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Kura Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | Bradley Canino | Stifel Nicolaus | $11.00 | $10.80 | 1.85% | 43.04% |
| Oct 24, 2024 | David Dai | UBS | $27.00 | $17.02 | 58.64% | 251.11% |
| Oct 14, 2024 | Bradley Canino | Stifel Nicolaus | $19.00 | $18.58 | 2.26% | 147.07% |
| Jun 25, 2024 | Joseph Pantginis | H.C. Wainwright | $32.00 | $21.08 | 51.80% | 316.12% |
| May 23, 2024 | Bradley Canino | Stifel Nicolaus | $28.00 | $21.43 | 30.66% | 264.11% |
| Dec 22, 2023 | Mara Goldstein | Mizuho Securities | $26.00 | $13.81 | 88.27% | 238.10% |
The latest Kura Oncology stock forecast, released on Nov 22, 2024 by Bradley Canino from Stifel Nicolaus, set a price target of $11.00, which represents a 1.85% increase from the stock price at the time of the forecast ($10.80), and a 43.04% increase from KURA last price ($7.69).
Kura Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 5 |
| Avg Price Target | - | $11.00 | $23.40 |
| Last Closing Price | $7.69 | $7.69 | $7.69 |
| Upside/Downside | -100.00% | 43.04% | 204.29% |
In the current month, the average price target of Kura Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kura Oncology's last price of $7.69. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Oct 24, 2024 | UBS | Buy | Initialise | |
| Jun 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Feb 25, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Feb 25, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Kura Oncology's last stock rating was published by H.C. Wainwright on Nov 18, 2024. The company gave KURA a "Buy" rating, the same as its previous rate.
Kura Oncology Financial Forecast
Kura Oncology Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $30.40M | $8.80M | $11.11M | - | $7.79M | - | - |
| High Forecast | $30.40M | $8.80M | $11.11M | - | $11.22M | - | - |
| Low Forecast | $30.40M | $8.80M | $11.11M | - | $934.99K | - | - |
| # Analysts | 4 | 3 | 4 | - | 8 | - | - |
| Surprise % | - | - | - | - | - | - | - |
Kura Oncology's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. KURA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Kura Oncology EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | - | 8 | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict KURA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kura Oncology's previous annual EBITDA (undefined) of $NaN.
Kura Oncology Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | - | 8 | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-38.83M | $-54.37M | $-48.60M | $-58.95M | $-55.30M | $-54.44M | $-54.24M |
| High Forecast | $-38.83M | $-54.37M | $-48.60M | $-58.12M | $-34.23M | $-54.44M | $-54.24M |
| Low Forecast | $-38.83M | $-54.37M | $-48.60M | $-59.78M | $-65.84M | $-54.44M | $-54.24M |
| Surprise % | - | - | - | - | - | - | - |
Kura Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KURA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kura Oncology SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | - | 8 | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Kura Oncology's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to KURA last annual SG&A of $NaN (undefined).
Kura Oncology EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | - | 8 | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.45 | $-0.63 | $-0.56 | $-0.68 | $-0.64 | $-0.63 | $-0.63 |
| High Forecast | $-0.45 | $-0.63 | $-0.56 | $-0.67 | $-0.39 | $-0.63 | $-0.63 |
| Low Forecast | $-0.45 | $-0.63 | $-0.56 | $-0.69 | $-0.76 | $-0.63 | $-0.63 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Kura Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KURA previous annual EPS of $NaN (undefined).
Kura Oncology Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals | $1.89 | $21.86 | 1056.61% | Buy |
| INZY | Inozyme Pharma | $1.42 | $16.00 | 1026.76% | Buy |
| LRMR | Larimar Therapeutics | $3.71 | $17.00 | 358.22% | Buy |
| ERAS | Erasca | $1.84 | $6.00 | 226.09% | Buy |
| KALV | KalVista Pharmaceuticals | $8.77 | $22.67 | 158.49% | Buy |
| KURA | Kura Oncology | $7.69 | $19.00 | 147.07% | Buy |
| SNDX | Syndax Pharmaceuticals | $14.24 | $30.60 | 114.89% | Buy |
| DSGN | Design Therapeutics | $4.94 | $9.67 | 95.75% | Buy |
| MRUS | Merus | $41.65 | $81.25 | 95.08% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.01 | $24.00 | 84.47% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $20.66 | $37.50 | 81.51% | Buy |
| CRNX | Crinetics Pharmaceuticals | $39.38 | $69.00 | 75.22% | Buy |
| REPL | Replimune Group | $14.07 | $23.00 | 63.47% | Buy |
| COGT | Cogent Biosciences | $9.30 | $14.50 | 55.91% | Buy |
| PTGX | Protagonist Therapeutics | $38.21 | $57.33 | 50.04% | Buy |
| VRDN | Viridian Therapeutics | $19.43 | $22.75 | 17.09% | Buy |